title: Thyroid effects and anticancer treatment.
abstract: Thyroid consequences of cancer therapy are multiple, better known after radiotherapy than after chemotherapy and recently described with targeted therapies. Cervical or total body irradiation may result in thyroid insufficiency or cancer. The consequences of treatment with new antiangiogenic drugs are under evaluation; however their effect on thyroid function is already well established. Thyroid dysfunction usually occurs late, several months or years after treatment and have to be depicted. There is an improvement in the overall survival of patients suffering from cancer and endocrinologists must be aware of the endocrine effects of treatments to propose an adequate survey and an appropriate treatment to improve well-being of patients.
authors.affiliation: Fédération d'endocrinologie du pôle Est, groupement hospitalier Est, Bron, France. cnozieres@yahoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Nozières
authors.forename: C
authors.initials: C
authors.lastname: Damatte-Fauchery
authors.forename: F
authors.initials: F
authors.lastname: Borson-Chazot
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008939:Mitotane / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D013959:Thyroid Diseases / Q000209:etiology*; D013960:Thyroid Function Tests
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D008939:Mitotane; C546842:MTOR protein, human; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases